Transcriptional targeting of adenovirally delivered tumor necrosis factor α by temozolomide in experimental glioblastoma

Cancer Research

Volumn 64, Issue 18, 2004, Pages 6381-6384

  Yamini, Bakhtiar ^a,d   Yu, Xiaohong ^a   Gillespie, G Yancey ^b   Kufe, Donald W ^c   Weichselbaum, Ralph R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Kentucky   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALKYLATING AGENT; COMPLEMENTARY DNA; CYTOKINE; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; EGRI GENE; FEMALE; FLOW CYTOMETRY; GENE INDUCTION; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SURVIVAL RATE; TUMOR XENOGRAFT;

ADENOVIRUSES, HUMAN; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 4644311756     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2117     Document Type: Article

References (20)

1. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-8.
2. Chang SM, Theodosopoulos P, Lamborn K, et al. Temozolomide in the treatment of recurrent malignant glioma. Cancer 2004;100:605-11.
3. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-82.
4. Old LJ. Tumor necrosis factor (TNF). Science 1985;230:630-2.
5. Spriggs DR, Sherman ML, Michie H, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion: a phase 1 and pharmacologic study. J Natl Cancer Inst (Bethesda) 1988;80:1039-44.
6. Manusama ER, Nooijen PT, Stavast J, Durante NM, Marquet RL, Eggermont AM. Synergistic antitumour effect of recombinant human tumour necrosis factor α with melphalan in isolated limb perfusion in the rat. Br J Surg 1996;83:551-5.
7. Park JO, Lopez CA, Gupta VK, et al. Transcriptional control of viral gene therapy by cisplatin. J Clin Investig 2002;110:403-10.
8. Staba MJ, Mauceri HJ, Kufe DW, Hallahan DE, Weichselbaum RR. Adenoviral TNF-α gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther 1998;5:293-300.
9. 2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 2001;61:1957-63.
10. Friedman HS, Dolan ME, Pegg AE, et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 1995;55:2853-7.
11. Lal S. Lacroix M, Tofilon P, Fuller GN, Sawaya R, Lang FF. An implantable guide-screw system for brain tumor studies in small animals. J Neurosurg 2000;92:326-33.
12. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998;31:1-9.
13. Duan L, Aoyagi M, Tamaki M, et al. Sensitization of human malignant glioma, cell lines to tumor necrosis factor-induced apoptosis by cisplatin. J Neurooncol 2001;52:23-36.
14. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000;6:2585-97.
15. Hammond LA, Eckardt JR, Baker SD, et al. Phase 1 and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 1999;17:2604-13.
16. Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003;4:429-37.
17. Duan L, Aoyagi M, Tamaki M, et al. Impairment of both apoptotic and cytoprotective signalings in glioma cells resistant to the combined use of cisplatin and tumor necrosis factor α. Clin Cancer Res 2004;10:234-43.
18. Raza SM, Lang FF, Aggarwal BB, Fuller GN, Wildrick DM, Sawaya R. Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis. Neurosurgery 2002;51:2-12; discussion 12-3.
19. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190-8.
20. Liang BC, Thornton AF Jr, Sandler HM, Greenberg HS. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 1991;75:559-63.